
Mentis Cura provides EEG-based tools and an AI-enabled data platform to improve diagnosis and clinical decision-making for central nervous system disorders. The company combines clinical EEG analysis with machine learning models and a unified data platform to support research, product development, and diagnostics. It operates as a B2B medical diagnostics and healthtech provider that partners with healthcare providers, researchers, and medical institutions and integrates with clinical workflows. Mentis Cura focuses on brain health conditions such as Alzheimer’s disease and ADHD for clinical and research applications in neurology.

Mentis Cura provides EEG-based tools and an AI-enabled data platform to improve diagnosis and clinical decision-making for central nervous system disorders. The company combines clinical EEG analysis with machine learning models and a unified data platform to support research, product development, and diagnostics. It operates as a B2B medical diagnostics and healthtech provider that partners with healthcare providers, researchers, and medical institutions and integrates with clinical workflows. Mentis Cura focuses on brain health conditions such as Alzheimer’s disease and ADHD for clinical and research applications in neurology.
What they do: EEG-based diagnostic tools and AI-enabled data platform for CNS disorders
Founded: 2004 (Reykjavík, Iceland)
Focus conditions: Alzheimer's disease, ADHD (clinical and research applications)
Business model: B2B medical diagnostics / R&D working with healthcare providers and researchers
Size (public profile): Listed as 1–10 employees
Diagnosis and clinical decision support for central nervous system (CNS) disorders
2004
Biotechnology
Public profiles list multiple grant and seed funding events between 2004 and 2013; last recorded funding date listed as 2013-03-01.
Seed investor listed as New Business Venture Fund in public profiles.
“Technology Development Fund and New Business Venture Fund are listed as lead/recurring investors in historical rounds”